
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AIT-102
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AI Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
Details : EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : AIT-102
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AI Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
